Our B-CAD platform and single B-cell sequencing workflows allow for rapid, high-affinity, and diverse antibody discovery directly from antigen specific memory B cells.
Key Platforms & Technologies
B-CAD B-cell Culture Platform
- Antigene specific single B cell sorting per well in 384-well plate
- B-cell culture up to 50–100 cells per well in 384-well format
- Culture media enriched with proprietary cytokines/growth factors
- Supernatant screening: ELISA, flow cytometry, Octet, SPR
- Turnaround Time (TAT): 2–3 weeks
Single B-cell Sequencing
- Direct recovery of V-genes from antigen-specific B cells
- Rapid reformatting, expression, and screening
- High diversity, improved developability
Advantages
- Faster timelines than traditional hybridoma workflows
- Greater antibody diversity and affinity range
- High developability and cost-effectiveness
- Compatible with high-throughput liquid handling
Why Choose Aurigene?
Proprietary B-cell culture platform enabling rapid antibody discovery
Antigen specific Mmemory B-cell selection for better candidates
Integrated sequencing and expression pipeline
Superior candidate quality and productivity
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Learning Resources
-
Development and assessment of a Bcs class II - SGLT2 (Sodium Glucose Cotransporter 2) inhibitor drug in the form of solid lipid Nanoparticles by selecting different lipids, co-surfactants, and manufacturing techniques
Drug Delivery System (DDS) has been used successfully in the past few decades to cure illnesses and enhance health because of its improved systemic circulation and ability to regulate the drug's pharmacological action. As pharmacology and pharmacokinetics advanced, the idea of controlled release emerged, demonstrating the significance of drug release in assessing...
Read More -
Development of novel paullone-based PROTACs as anticancer agents
Proteolysis-targeting chimera (PROTACs) represents a promising modality that has gained significant attention for cancer treatment. Using PROTAC technology, we synthesized novel structurally modified paullone-based PROTACs using Cereblon (CRBN) and Von Hippel–Lindau (VHL) E3 ligands....
Read More -
Development and verification of RP-HPLC method for the quantitative determination of Decitabine in tablet dosage formulation
Decitabine is an anti-cancer chemotherapy drug. This article describes method development and method verification of Assay of Decitabine in tablet formulation. A new, precise, rapid, accurate RP-HPLC method has been developed for the estimation of Decitabine in pharmaceutical tablets dosage form. After optimization the good chromatographic separation was achieved...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market